Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer

Gynecologic Oncology

Volumn 134, Issue 1, 2014, Pages 112-120

  Arend, Rebecca C ^a   Londoño Joshi, Angelina I ^b   Samant, Rajeev S ^b   Li, Yonghe ^c   Conner, Michael ^b   Hidalgo, Bertha ^c   Alvarez, Ronald D ^a   Landen, Charles N ^a   Straughn, J Michael ^a   Buchsbaum, Donald J ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d The University of Alabama at Birmingham   (United States)

Author keywords

Cancer stem cells; Chemoresistance; LRP6; Niclosamide; Ovarian cancer; Wnt catenin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDEHYDE DEHYDROGENASE; AXIN; BETA CATENIN; CARBOPLATIN; CD133 ANTIGEN; CYCLIN D1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NICLOSAMIDE; SURVIVIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASCITES TUMOR CELL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MONOTHERAPY; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; SOLID TUMOR; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ASCITES; CANCER PATIENT; DRUG CYTOTOXICITY; IN VITRO STUDY;

CANCER STEM CELLS; CHEMORESISTANCE; LRP6; NICLOSAMIDE; OVARIAN CANCER; WNT/Β-CATENIN;

ALDEHYDE DEHYDROGENASE; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CARBOPLATIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; NICLOSAMIDE; OVARIAN NEOPLASMS; PEPTIDES; WNT SIGNALING PATHWAY;

EID: 84903120790     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.04.005     Document Type: Article

References (38)

1. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
3. J. Sandercock, M.K. Parmar, V. Torri, and W. Qian First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence Br J Cancer 87 2002 815 824 (Pubitemid 35252955)
4. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
5. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
6. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki et al. Japanese Gynecologic Oncology G. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
7. R.T. Penson, D.S. Dizon, S.A. Cannistra, M.R. Roche, C.N. Krasner, and S.T. Berlin et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors J Clin Oncol 28 2010 154 159
8. F. Ricci, S. Bernasconi, P. Perego, M. Ganzinelli, G. Russo, and F. Bono et al. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype Cell Cycle 11 2012 1966 1976
9. C. Raimondi, W. Gianni, E. Cortesi, and P. Gazzaniga Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease Curr Cancer Drug Targets 10 2010 496 508
10. A. Wieland, D. Trageser, S. Gogolok, R. Reinartz, H. Hofer, and M. Keller et al. Anticancer effects of niclosamide in human glioblastoma Clin Cancer Res 19 2013 4124 4136
11. Y.T. Yo, Y.W. Lin, Y.C. Wang, C. Balch, R.L. Huang, and M.W. Chan et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide Mol Cancer Ther 11 2012 1703 1712
12. W. Lu, C. Lin, M.J. Roberts, W.R. Waud, G.A. Piazza, and Y. Li Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway PLoS One 6 2011 e29290
13. M. Chen, J. Wang, J. Lu, M.C. Bond, X.R. Ren, and H.K. Lyerly et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 48 2009 10267 10274
14. A. Mitra, M.E. Menezes, L.A. Shevde, and R.S. Samant DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype J Biol Chem 285 2010 24686 24694
15. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 2006 621 681
16. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
17. S.A. Bapat, A.M. Mali, C.B. Koppikar, and N.K. Kurrey Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer Cancer Res 65 2005 3025 3029 (Pubitemid 40524578)
18. J.A. Magee, E. Piskounova, and S.J. Morrison Cancer stem cells: impact, heterogeneity, and uncertainty Cancer Cell 21 2012 283 296
19. A. Latifi, K. Abubaker, N. Castrechini, A.C. Ward, C. Liongue, and F. Dobill et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile J Cell Biochem 112 2011 2850 2864
20. K. Abubaker, A. Latifi, R. Luwor, S. Nazaretian, H. Zhu, and M.A. Quinn et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden Mol Cancer 12 2013 24
21. S. Zhang, C. Balch, M.W. Chan, H.C. Lai, D. Matei, and J.M. Schilder et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res 68 2008 4311 4320
22. I. Kryczek, S. Liu, M. Roh, L. Vatan, W. Szeliga, and S. Wei et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells Int J Cancer 130 2012 29 39
23. M. Verras, and Z. Sun Roles and regulation of Wnt signaling and beta-catenin in prostate cancer Cancer Lett 237 2006 22 32
24. P. Wend, J.D. Holland, U. Ziebold, and W. Birchmeier Wnt signaling in stem and cancer stem cells Semin Cell Dev Biol 21 2010 855 863
25. A. Latifi, R.B. Luwor, M. Bilandzic, S. Nazaretian, K. Stenvers, and J. Pyman et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors PLoS One 7 2012 e46858
26. M.D. Curley, L.A. Garrett, J.O. Schorge, R. Foster, and B.R. Rueda Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer Front Biosci (Landmark Ed) 16 2011 368 392
27. C. Aguilar-Gallardo, E.C. Rutledge, A.M. Martinez-Arroyo, J.J. Hidalgo, S. Domingo, and C. Simon Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches Stem Cell Rev 8 2012 994 1010
28. N. Ahmed, K. Abubaker, J. Findlay, and M. Quinn Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance J Cell Biochem 114 2013 21 34
29. F. Takahashi-Yanaga, and M. Kahn Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16 2010 3153 3162
30. J.M. Gonzalez-Sancho, K.R. Brennan, L.A. Castelo-Soccio, and A.M. Brown Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin Mol Cell Biol 24 2004 4757 4768 (Pubitemid 38668042)
31. A. Kikuchi, H. Yamamoto, and S. Kishida Multiplicity of the interactions of Wnt proteins and their receptors Cell Signal 19 2007 659 671 (Pubitemid 46275377)
32. M. Molenaar, M. van de Wetering, M. Oosterwegel, J. Peterson-Maduro, S. Godsave, and V. Korinek et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos Cell 86 1996 391 399 (Pubitemid 26272079)
33. E.E. Noel, M. Yeste-Velasco, X. Mao, J. Perry, S.C. Kudahetti, and N.F. Li et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers Am J Pathol 176 2010 2607 2615
34. J. Jiao, L. Huang, F. Ye, M. Shi, X. Cheng, and X. Wang et al. Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells Onco Targets Ther 6 2013 667 677
35. Y. Jin, Z. Lu, K. Ding, J. Li, X. Du, and C. Chen et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res 70 2010 2516 2527
36. J.X. Pan, K. Ding, and C.Y. Wang Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells Chin J Cancer 31 2012 178 184
37. T. Osada, M. Chen, X.Y. Yang, I. Spasojevic, J.B. Vandeusen, and D. Hsu et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res 71 2011 4172 4182
38. Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70